Table 4 Comparison of clinical and demographic characteristics of rheumatoid arthritis patients according to thyroid status (hypothyroidism vs. Euthyroidism).

From: Prevalence and impact of thyroid dysfunction in patients with rheumatoid arthritis

 

Hypothyroidism (n = 10)

Euthyroidism (n = 47)

p

Age (years) (mean ± SD)

54.3 ± 13.7

51.6 ± 14.4

0.585

Hypertension

Yes

3 (30%)

15 (32%)

1.000

No

7 (70%)

32 (68%)

Diabetes

Yes

0 (0%)

9 (19%)

1.000

No

10 (100%)

38 (81%)

Dyslipidemia

Yes

6 (60%)

30 (64%)

1.000

No

4 (40%)

17 (36%)

Overweight or obesity

Yes

7 (70%)

28 (60%)

1.000

No

3 (30%)

19 (40%)

Age of onset (years)

 

44[37; 53]

40[29.67;49.00]

0.326

Duration of disease (years)

13,13 [1,13; 14,32]

9,19[3,16; 21,17]

0.428

 DAS28 crp

4.49 [3.25–5.28]

3.92 [2.95–5.26]

0.629

 NSJ

5.6 ± 5.6

5.2 ± 5.2

0.814

 NTJ

7 ± 5.63

6.9 ± 6.6

0.956

 CRP

11.8 ± 7.8

20.8 ± 34.2

0.414

 VAS

4.6 ± 2.2

5.3 ± 2.4

0.428

 HAQ

1.5 [1.38–1.75]

1.5 [1.2–1.75]

0.690

ACPA

Positive

8 (80%)

27 (57%)

0.287

Negative

2 (20%)

20 (43%)

ANA

Positive

2 (20%)

9 (19%)

1.000

Negative

8 (80%)

38 (81%)

RF

Positive

8 (80%)

37 (79%)

1.000

Negative

2 (20%)

10 (21%)

Erosions

Present

7 (70%)

16 (33.3%)

1.000

Absent

3 (30%)

32 (66.6%)

  1. N, Number; p, Significance; SD, Standard deviation; DAS28, Disease activity score, NSJ, Number of swollen joints; NTJ, Number of tender joints; CRP, C-Reactive protein; VAS, Visual Analogue Scale; HAQ, Health Assessment Questionnaire; ACPA, Anti-cyclic citrullinated peptide antibodies; ANA, Antinuclear antibodies; RF, Rheumatoid factor.